Surgery Doctors in Midwest City, OK Accepting Medicare

6 Surgery doctors found. Showing 1 - 6

Jahanyar John Makipour, Jr, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 9020 E Reno Ave Fl 2, Midwest City, OK 73130 Phone: 405-732-7715

Richard L Wilson, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2801 Parklawn Dr, Ste 303, Midwest City, OK 73110 Phone: 405-733-3030    Fax: 405-733-3865

Carlos Adrian Egas, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2801 Parklawn Dr Ste 300, Midwest City, OK 73110 Phone: 405-610-2400    Fax: 405-610-2411

Theodore A Ruff, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1001 S Douglas Blvd, Suite A, Midwest City, OK 73130 Phone: 405-733-3030    Fax: 405-733-3865

Dr. Ganga M Pujari, MD Surgery Medicare: Medicare Enrolled Practice Location: 6908 E Reno Ave, Suite 104, Midwest City, OK 73110 Phone: 405-736-0055    Fax: 405-736-6311

Lee Andrew Ison, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2817 Parklawn Dr, Midwest City, OK 73110 Phone: 405-737-6606    Fax: 405-737-2869

News Archive

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

QLT Inc. today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types).

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

The cost of insurance co-payments for cutting-edge pharmaceuticals can vary widely from patient to patient. When the patient's share of prescription costs becomes too high, many patients skip doses or stop taking medication entirely, according to research conducted at the University of North Carolina.

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of diabetic neuropathy, a drug that has disease-modifying potential would earn 40 percent patient share in the U.S., according to surveyed U.S. neurologists. Similarly, in Europe, such a drug would earn a comparable patient share of 43 percent, according to surveyed European neurologists.

Trimeris, Roche collaborate to commercialize FUZEON product

Trimeris, Inc., announced today that the Company and its partner, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., have entered into an agreement relieving Trimeris of any obligation to repay certain deferred marketing expenses.

Read more Medical News

› Verified 6 days ago